Fibromyalgia Treatment Market Outlook:
Fibromyalgia Treatment Market size was over USD 3.2 billion in 2025 and is projected to reach USD 4.69 billion by 2035, witnessing around 3.9% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of fibromyalgia treatment is evaluated at USD 3.31 billion.
The growth of the market is primarily ascribed to the worldwide escalating load of chronic pain. Fibromyalgia, according to researchers, increases painful sensations by altering how the brain and spinal cord receive painful and non-painful impulses. As per the World Health Organization (WHO), nearly 1.71 billion people around the world have been suffering from musculoskeletal disorders.
Fibromyalgia, commonly known as fibromyalgia syndrome, is a severe neurologic condition that results in immense pain throughout the body. This condition affects people physically, intellectually, and socially and causes exhaustion, musculoskeletal pain, and localized discomfort. Furthermore, there are only a few drugs, such as milnacipran, and pregabalin which are prescribed for fibromyalgia treatment. Globally rising occurrence of musculoskeletal disorder is leading to increased chances of fibromyalgia. According to the National Fibromyalgia Association, fibromyalgia affects an estimated 10 million people in the United States.
Key Fibromyalgia Treatment Market Insights Summary:
Regional Highlights:
- The North America fibromyalgia treatment market will hold over 42.9% share by 2035, driven by increasing prevalence and rising awareness of fibromyalgia.
Segment Insights:
- The antiepileptics segment in the fibromyalgia treatment market is anticipated to hold the largest share by 2035, driven by the effectiveness of pregabalin in reducing fibromyalgia pain.
- The retail pharmacies segment in the fibromyalgia treatment market is expected to capture a significant share by 2035, fueled by convenience and non-hospital-based treatment options for fibromyalgia.
Key Growth Trends:
- Growing Prevalence of Fibromyalgia Treatmen
- Increasing Government Initiatives
Major Challenges:
- Growing Prevalence of Fibromyalgia Treatmen
- Increasing Government Initiatives
Key Players: Pfizer Inc., AbbVie Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Aptinyx Inc., Tonix Pharmaceuticals Holding Corp., Virios Therapeutics.
Global Fibromyalgia Treatment Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2025 Market Size: USD 3.2 billion
- 2026 Market Size: USD 3.31 billion
- Projected Market Size: USD 4.69 billion by 2035
- Growth Forecasts: 3.9% CAGR (2026-2035)
Key Regional Dynamics:
- Largest Region: North America (42.9% Share by 2035)
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, China, Germany, Japan, United Kingdom
- Emerging Countries: China, India, Japan, South Korea, Singapore
Last updated on : 10 September, 2025
Fibromyalgia Treatment Market Growth Drivers and Challenges:
Growth Drivers
- Growing Prevalence of Fibromyalgia Treatment- There are numerous factors that is expected to drive the global fibromyalgia treatment market’s growth. However, the primary factor that is anticipated to grow the market is the rise in fibromyalgia globally. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), 5 million Americans who are 18 years of age or older have fibromyalgia, and females make up between 80 and 90 percent of fibromyalgia patients. Additionally, there were nearly 1.75 million adults in England and Wales with fibromyalgia as of 2019.
- Increasing Government Initiatives - It is predicted that the market will increase as a result of the growing government initiatives that provide manufacturers and medical practitioners with guidance regarding fibromyalgia. For instance, the European League Against Rheumatism (EULAR) advised against using non-steroidal anti-inflammatory medicines (NSAID) to treat fibromyalgia in their 2016 recommendations. According to estimates, these policies will assist the affected population to manage their fibromyalgia and raise awareness of the condition.
- Worldwide Growing Incidences of Road Accidents - Road accidents are the most dreadful thing that happens to a road user, even though they occur quite frequently. The majority of fatal accidents are caused by excessive speeding, the use of alcohol, or any psychoactive substance or drug. These factors raise the risk of road accidents resulting in death or serious injury. Many times, the surviving person phases long-term disability or severe pain which turns into fibromyalgia disorder over time. Thus, increasing road accidents lead to the growing prevalence of fibromyalgia disorder. According to the World Health Organization statistics, road accidents claim the lives of around 1.3 million people every year across the globe. There are an additional 20 to 50 million people who sustain non-fatal injuries, many of whom proceed to suffer disabilities.
- Surge in Novel Drug Development – Chronic illness fibromyalgia substantially limits patients' ability to engage in typical social and professional activities and makes it difficult to maintain relationships with friends, family, and co-workers. The full spectrum of pain, tiredness, sleep disturbances, and depression symptoms is not completely addressed by any of the medicines currently available. However, the pharmaceutical industry's expanding endeavors have led to the launch of new experimental treatments by deploying novel drug delivery systems, a novel combination of already-approved drugs, as well as inquiries into the potential for using drugs already being prescribed for other ailments. For instance, in 2021, following a pre-NDA meeting with the US Food and Drug Administration, Axsome Therapeutics, Inc., which develops novel therapies for the treatment of central nervous system (CNS) disorders, announced its decision to submit a New Drug Application (NDA) for AXS-14 for the treatment of fibromyalgia (FDA). AXS-14 (esreboxetine) is a new oral, norepinephrine reuptake inhibitor that is both potent and selective.
- Worldwide Boost in the Population of People Above 60- As per the data released by the World Health Organization, the worldwide population of people aged 60 and over is projected to propagate from 1 billion in 2020 to 1.4 billion by 2030. By 2050, the world's population of people aged 60 and above is anticipated to double by 2.1 billion.
Challenges
- High Adoption of Generic Drugs - Only three medications are currently specifically licensed for the treatment of fibromyalgia. As a result, off-label medications and generic antidepressants are being used more frequently to treat the disease's symptoms. Therefore, it is expected to hamper the market’s growth.
- Side Effects Associated with the Use of Fibromyalgia Drugs - Suicidal ideation may be increased in some persons by certain medications. Nausea, headache, exhaustion, high blood pressure, racing heart, excessive sweating, agitation, cholesterol, triglyceride increase, and tremor are all possible side effects.
- Stringent Regulations of Government
Fibromyalgia Treatment Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Period |
2026-2035 |
|
CAGR |
3.9% |
|
Base Year Market Size (2025) |
USD 3.2 billion |
|
Forecast Year Market Size (2035) |
USD 4.69 billion |
|
Regional Scope |
|
Fibromyalgia Treatment Market Segmentation:
Drug Class
The global fibromyalgia treatment market is segmented and analyzed for demand and supply by drug class into antidepressants, antiepileptics, muscle relaxants, and others. Out of the these, types of drug-class antiepileptics segment is estimated to gain the largest market share over the projected time frame. Anticonvulsants, usually referred to as antiepileptic medications, are frequently prescribed to treat epilepsy, and on the other hand, they have also been used to treat fibromyalgia. The FDA has approved the antiepileptic drug pregabalin for the treatment of fibromyalgia. Pregabalin blocks the release of substances P, norepinephrine, and glutamate, which may significantly help fibromyalgia patients feel less pain. Depending on the patient's creatinine clearance, pregabalin must be begun at 75 mg twice daily and gradually increased to 225 mg twice daily. Total daily doses of 300 mg, 450 mg, or 600 mg can lessen pain by more than 30% if the patient can bear the side effects of drowsiness, dry mouth, added weight, and oedema. The market for antidepressants, is anticipated to hold the second largest share over the forecast period. The signs of depression may be lessened with the aid of antidepressants. Additionally, they can help in the treatment of seasonal affective disorder and social anxiety disorder. There is growing evidence that, to a limited extent, antidepressants are effective therapies for fibromyalgia. Antidepressants change specific neurotransmitters in the brain, and these same neurotransmitters play a role in fibromyalgia. One of the most popular forms of treatment is amitriptyline and other tricyclic antidepressants (TCAs). Newer antidepressants have undergone thorough fibromyalgia testing since they are better tolerated than tricyclics. Instead of acting as an antidepressant, cyclobenzaprine, a tricyclic substance that varies from amitriptyline only by one double bond, relaxes the muscles.
Distribution Channel
The global fibromyalgia treatment market is also segmented and analyzed for distribution by distribution into retail pharmacies, hospital pharmacies, and online pharmacies. Amongst these three segments, the retail pharmacies segment is expected to garner a significant share. Any pharmacy that dispenses, stocks, or sells prescription drugs to the general public is considered retail pharmacy. Any consumer can pick up their medication at a retail pharmacy without first acquiring a prescription. Moreover, the customers have direct contact with the retailer. A reputable company that sells medicines and related goods is a retail pharmacy. Since hospitalization is not always necessary for fibromyalgia therapy, retail pharmacies are expected to gain market share during the anticipated period. Hospital pharmacies, which were expected to expand at the greatest CAGR. Integrated into the care of a medical facility is the subsection of pharmacy known as a hospital pharmacy. These include residential care institutions, hospitals, outpatient clinics, drug addiction treatment centers, poison control centers, and drug resource centers. The job involves choosing, preparing, storing, compounding, and dispensing drugs for patients in a medical setting. Hospital pharmacies' primary responsibility in patient care is risk management.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Type |
|
|
By Distribution |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Fibromyalgia Treatment Market Regional Analysis:
APAC Market Insights
The Asia-Pacific market is anticipated to increase steadily throughout the course of the forecast period. Aspects such as the growing number of fibromyalgia patients, along with rising healthcare spending and developing healthcare infrastructure, are predicted to boost the market growth in the Asia Pacific.
North American Market Insights
North America region is likely to hold over 42.9% market share by 2035, driven by increasing prevalence and rising awareness of fibromyalgia. As per the Centers for Disease Control and Prevention, fibromyalgia affects approximately 4 million adults in the United States, accounting for approximately 2% of the adult population.
Fibromyalgia Treatment Market Players:
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AbbVie Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Aptinyx Inc.
- Tonix Pharmaceuticals Holding Corp.
- Virios Therapeutics
Recent Developments
-
Aptinyx Inc. declared the completion of the enrolment of 305 patients in the current Phase 2b study of NYX-2925 in fibromyalgia. NYX-2925 is being studied in 305 patients with fibromyalgia in a randomized, double-blind, placebo-controlled Phase 2 study.
-
Astellas Pharma Inc. has acquired bioelectronics start-up company Iota Biosciences, Inc. Astellas' Rx+ projects are estimated to accelerate in light of this acquisition.
- Report ID: 4467
- Published Date: Sep 10, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Fibromyalgia Treatment Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
Copyright @ 2025 Research Nester. All Rights Reserved.
